VANCOUVER, July 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the second quarter ended June 30, 2010. "We are pleased to report continued quarter over quarter growth in product sales, driven primarily by our most innovative Proprietary Medical Products," said Dr. William Hunter, President and CEO of Angiotech. "In ...

The use of EBITDA by the Company has certain material limitations because it excludes the recurring expenditures of interest, income tax, and amortization ...

As a result, Information and Trading Systems costs were reduced in Q2/10 and amortization of the related costs was higher (see Amortization) when compared ...

The sequential quarter decline in total gross loans is primarily attributable to scheduled amortization, loan prepayments, and charge-offs. ...

The sequential quarter decline in total gross loans is primarily attributable to scheduled amortization, loan prepayments, and charge-offs. ...

The use of EBITDA by the Company has certain material limitations because it excludes the recurring expenditures of interest, income tax, and amortization ...

You will easily find several packages that feature fixed rate or variable rate mortgages with amortization terms up to 20 years. ...

The sequential quarter decline in total gross loans is primarily attributable to scheduled amortization, loan prepayments, and charge-offs. ...

By 2006, more than one-third of subprime mortgages had amortization schedules longer than 30 years, nearly half of Alt-A mortgages were interest-only, ...

The sequential quarter decline in total gross loans is primarily attributable to scheduled amortization, loan prepayments, and charge-offs. ...